APA (7th ed.) Citation

Taramasso, L., Di Biagio, A., Maggiolo, F., Tavelli, A., Lo Caputo, S., Bonora, S., . . . Group, t. I. C. N. A. F. S. (2018). First‐line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: A durability comparison. HIV Medicine, 19(7), 475. https://doi.org/10.1111/hiv.12628

Chicago Style (17th ed.) Citation

Taramasso, L., et al. "First‐line Antiretroviral Therapy with Efavirenz Plus Tenofovir Disiproxil Fumarate/emtricitabine or Rilpivirine Plus Tenofovir Disiproxil Fumarate/emtricitabine: A Durability Comparison." HIV Medicine 19, no. 7 (2018): 475. https://doi.org/10.1111/hiv.12628.

MLA (9th ed.) Citation

Taramasso, L., et al. "First‐line Antiretroviral Therapy with Efavirenz Plus Tenofovir Disiproxil Fumarate/emtricitabine or Rilpivirine Plus Tenofovir Disiproxil Fumarate/emtricitabine: A Durability Comparison." HIV Medicine, vol. 19, no. 7, 2018, p. 475, https://doi.org/10.1111/hiv.12628.